According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

New research shows white blood cells activated by COVID-19 may have cancer-fighting abilities, offering hope for future ...

See now: Merck says trial of combination treatment for colon cancer failed to meet main goal PD-L1 is found in healthy cells ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

which is indicated for use alongside PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel in adult patients with metastatic non ...

For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Is ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Merck’s phase 3 trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints: Rahway, New Jersey Thursday, November 21, 2024, 10:00 Hrs [IST] Merck, k ...

上海2024年11月17日 /美通社/ -- 君实生 物（1877.HK，688180.SH）宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗（英国商品名：LOQTORZI? ）于近日获得英国药品... 上海2024年11月17日 /美通社/ -- 君实生物（1877.HK，688180.SH）宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗（英国商品名：LOQTORZI ® ）于近日获得 ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.